| Business Summary | | Enzon
Inc.
is
a
biopharmaceutical
company
that
develops
and
commercializes
enhanced
therapeutics
for
life-threatening
diseases
through
the
application
of
its
two
proprietary
platform
technologies:
polyethylene
glycol
(PEG)
and
single-chain
antibody
(SCA).
The
Company
applies
its
PEG
technology
to
improve
the
delivery,
safety
and
efficacy
of
proteins
and
small
molecules
with
known
therapeutic
efficacy.
The
Company
applies
its
single-chain
antibody
technology
to
discover
and
produce
antibody-like
molecules
that
offer
many
of
the
therapeutic
benefits
of
monoclonal
antibodies,
while
addressing
some
of
their
limitations. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Enzon,
Inc.
is
a
biopharmaceutical
company
that
develops,
manufactures
and
markets
enhanced
therapeutics
for
life-threatening
diseases
through
the
application
of
its
proprietary
technologies.
For
the
nine
months
ended
3/31/01,
revenues
rose
70%
to
$21.1
million.
Net
income
applicable
to
Common
totaled
$8.2
million
vs.
a
loss
of
$5.3
million.
Results
reflect
increased
ONCASPAR
sales
and
royalties
earned
on
sales
of
PEG-INTRON,
and
the
absence
of
an
inventory
write-off. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
10,463;
after
tax
earnings
were
3,308. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Randy Thurman, 51 Chairman | -- | Arthur Higgins, 45 Pres,
CEO | -- | Kenneth Zuerblis, 41 CFO,
VP-Fin., Sec. | $267K | Norman Hardman, Ph.D. Sr.
VP of Technology | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|